While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
INTERVIEW
JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
Now that Japan has decided to introduce a cost-effectiveness assessment (CEA) system in April 2019, we are interviewing key stakeholders and policymakers about their views on the government’s proposal and challenges it might face going forward. For the first of…
To read the full story
Related Article
- Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
April 23, 2019
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
- With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
April 5, 2019
- Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
April 3, 2019
- Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
March 29, 2019
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
INTERVIEW
- From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
- Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
- Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
- “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
- Causes of NDMA Contamination Scandal Still under Investigation: NIHS Division of Drugs
January 27, 2020
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…